This HTML5 document contains 52 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n9http://linked.opendata.cz/resource/drugbank/drug/DB01369/identifier/pharmgkb/
dctermshttp://purl.org/dc/terms/
n8http://linked.opendata.cz/resource/drugbank/drug/DB01369/identifier/wikipedia/
n16http://linked.opendata.cz/resource/drugbank/drug/DB01369/identifier/kegg-compound/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01369/identifier/pdb/
n12http://linked.opendata.cz/resource/drugbank/company/
n11http://linked.opendata.cz/resource/drugbank/mixture/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01369/identifier/kegg-drug/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01369/identifier/drugbank/
n6http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n10http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB01369
rdf:type
n3:Drug
n3:description
Quinupristin/dalfopristin is a combination of two antibiotics used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis. The combination of the two components acts synergistically and is more effective in vitro than each component alone.
n3:generalReferences
# Allington DR, Rivey MP: Quinupristin/dalfopristin: a therapeutic review. Clin Ther. 2001 Jan;23(1):24-44. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11219478 # Lamb HM, Figgitt DP, Faulds D: Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections. Drugs. 1999 Dec;58(6):1061-97. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10651391 # Manzella JP: Quinupristin-dalfopristin: a new antibiotic for severe gram-positive infections. Am Fam Physician. 2001 Dec 1;64(11):1863-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11764864 # Paradisi F, Corti G, Messeri D: Antistaphylococcal (MSSA, MRSA, MSSE, MRSE) antibiotics. Med Clin North Am. 2001 Jan;85(1):1-17. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11190346
n3:group
approved
n3:halfLife
3.1 hours
n3:indication
For the treatment of bacterial infections (usually in combination with dalfopristin).
owl:sameAs
n6:DB01369 n10:DB01369
dcterms:title
Quinupristin
adms:identifier
n8:Quinupristin n9:PA164749647 n13:D00852 n14:SYB n15:DB01369 n16:C08032
n3:mechanismOfAction
Quinupristin inhibits the late phase of protein synthesis in the bacterial ribosome. Dalfopristin binds to the 23S portion of the 50S ribosomal subunit, and changes the conformation it, enhancing the binding of quinupristin by a factor of about 100. In addition, it inhibits peptidyl transferase. Quinupristin binds to a nearby site on the 50S ribosomal subunit and prevents elongation of the polypeptide as well as causing incomplete chains to be released.
n3:packager
n12:271B4329-363D-11E5-9242-09173F13E4C5 n12:271B4327-363D-11E5-9242-09173F13E4C5 n12:271B4328-363D-11E5-9242-09173F13E4C5 n12:271B4326-363D-11E5-9242-09173F13E4C5
n3:mixture
n11:271B4325-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
Moderate.
n3:IUPAC-Name
n4:271B432E-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4334-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4333-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4330-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4331-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4332-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B432C-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B432D-363D-11E5-9242-09173F13E4C5 n4:271B432A-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B432B-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B433A-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B433B-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4335-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4336-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4338-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4337-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4339-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Enterococcus faecalis Enteric bacteria and other eubacteria
n3:casRegistryNumber
120138-50-3
n3:category
n3:Bioavailability
n4:271B4340-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4342-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4343-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B433F-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B433E-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4341-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B432F-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B433C-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B433D-363D-11E5-9242-09173F13E4C5